188 related articles for article (PubMed ID: 33333396)
1. Development of Mcl-1 inhibitors for cancer therapy.
Negi A; Murphy PV
Eur J Med Chem; 2021 Jan; 210():113038. PubMed ID: 33333396
[TBL] [Abstract][Full Text] [Related]
2. Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.
Wan Y; Dai N; Tang Z; Fang H
Eur J Med Chem; 2018 Feb; 146():471-482. PubMed ID: 29407973
[TBL] [Abstract][Full Text] [Related]
3. MCL-1 inhibitors - where are we now (2019)?
Fletcher S
Expert Opin Ther Pat; 2019 Nov; 29(11):909-919. PubMed ID: 31566022
[No Abstract] [Full Text] [Related]
4. Recent Advances in the Development of Selective Mcl-1 Inhibitors for the Treatment of Cancer (2017-Present).
Fan Y; Hou X; Fang H
Recent Pat Anticancer Drug Discov; 2020; 15(4):306-320. PubMed ID: 32938354
[TBL] [Abstract][Full Text] [Related]
5. MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents.
Bolomsky A; Vogler M; Köse MC; Heckman CA; Ehx G; Ludwig H; Caers J
J Hematol Oncol; 2020 Dec; 13(1):173. PubMed ID: 33308268
[TBL] [Abstract][Full Text] [Related]
6. Molecular Comprehension of Mcl-1: From Gene Structure to Cancer Therapy.
Senichkin VV; Streletskaia AY; Zhivotovsky B; Kopeina GS
Trends Cell Biol; 2019 Jul; 29(7):549-562. PubMed ID: 31030977
[TBL] [Abstract][Full Text] [Related]
7. Mcl-1 as a "barrier" in cancer treatment: Can we target it now?
Pervushin NV; Senichkin VV; Zhivotovsky B; Kopeina GS
Int Rev Cell Mol Biol; 2020; 351():23-55. PubMed ID: 32247581
[TBL] [Abstract][Full Text] [Related]
8. Myeloid cell leukemin-1 inhibitors: a growing arsenal for cancer therapy.
Zhu PJ; Yu ZZ; You QD; Jiang ZY
Drug Discov Today; 2020 Oct; 25(10):1873-1882. PubMed ID: 32771436
[TBL] [Abstract][Full Text] [Related]
9. Recent Advances in Cancer Drug Development: Targeting Induced Myeloid Cell Leukemia-1 (Mcl-1) Differentiation Protein.
Abid M; Sonawane YA; Contreras JI; Rana S; Natarajan A
Curr Med Chem; 2017; 24(40):4488-4514. PubMed ID: 28901269
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of dual Bcl-2/Mcl-1 inhibitors bearing 2-(1H-indol-4-yl)benzoic acid scaffold.
Niu Q; Deng H; Zhang Z; Xu Q; Luan S; Huang M; Liu D; Zhao L
Bioorg Med Chem Lett; 2021 Sep; 47():128215. PubMed ID: 34153472
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and preliminary biological studies of pyrrolidine derivatives as Mcl-1 inhibitors.
Wan Y; Wang J; Sun F; Chen M; Hou X; Fang H
Bioorg Med Chem; 2015 Dec; 23(24):7685-93. PubMed ID: 26620718
[TBL] [Abstract][Full Text] [Related]
12. Small molecule Mcl-1 inhibitors for the treatment of cancer.
Belmar J; Fesik SW
Pharmacol Ther; 2015 Jan; 145():76-84. PubMed ID: 25172548
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in the development of Mcl-1 inhibitors for cancer therapy.
Hird AW; Tron AE
Pharmacol Ther; 2019 Jun; 198():59-67. PubMed ID: 30790641
[TBL] [Abstract][Full Text] [Related]
14. Identification of Small-Molecule Inhibitors of the Antiapoptotic Protein Myeloid Cell Leukaemia-1 (Mcl-1).
Beekman AM; O'Connell MA; Howell LA
ChemMedChem; 2016 Apr; 11(8):840-4. PubMed ID: 26616140
[TBL] [Abstract][Full Text] [Related]
15. Improved binding affinities of pyrrolidine derivatives as Mcl-1 inhibitors by modifying amino acid side chains.
Wan Y; Liu T; Li X; Chen C; Fang H
Bioorg Med Chem; 2017 Jan; 25(1):138-152. PubMed ID: 27810438
[TBL] [Abstract][Full Text] [Related]
16. Mcl-1 inhibitors: a patent review.
Chen L; Fletcher S
Expert Opin Ther Pat; 2017 Feb; 27(2):163-178. PubMed ID: 27744724
[TBL] [Abstract][Full Text] [Related]
17. Structure-Based Optimization of 3-Phenyl-
Li Y; Fan W; Gong Q; Tian J; Zhou M; Li Q; Uwituze LB; Zhang Z; Hong R; Wang R
J Med Chem; 2021 Jul; 64(14):10260-10285. PubMed ID: 34228434
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of tyrosine derivatives as Mcl-1 inhibitors.
Liu L; Liu R; Yang X; Hou X; Fang H
Eur J Med Chem; 2020 Apr; 191():112142. PubMed ID: 32088497
[TBL] [Abstract][Full Text] [Related]
19. Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells.
Doi K; Gowda K; Liu Q; Lin JM; Sung SS; Dower C; Claxton D; Loughran TP; Amin S; Wang HG
Cancer Biol Ther; 2014; 15(12):1688-99. PubMed ID: 25535900
[TBL] [Abstract][Full Text] [Related]
20. 1-Phenyl-1H-indole derivatives as a new class of Bcl-2/Mcl-1 dual inhibitors: Design, synthesis, and preliminary biological evaluation.
Xu G; Liu T; Zhou Y; Yang X; Fang H
Bioorg Med Chem; 2017 Oct; 25(20):5548-5556. PubMed ID: 28866374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]